Skip to content
Get BIO’s view on everything from health care to biofuels and the bioeconomy. The below articles include BIO statements, opinion, and calls to action, as well as articles and op-eds written by BIO leadership.
Prescription drug prices climbed more slowly than overall healthcare costs, according to the most recent health sector economic indicators from Altarum. In addition, healthcare […]
Prescription drug prices lag inflation, say new economic indicators Read More »
Paying for healthcare in the United States has been a challenging and controversial issue for years. In a landscape managed by private insurers, Medicaid,
To ensure access for all, healthcare payment models need innovation Read More »
While midterms results are still being tallied, we know a few key election results—and these results can give us some early insight into the
What we know (so far) the day after the midterms Read More »
At the Pantheon Awards 2022 event on Thursday, California Life Sciences (CLS) honored three Biotechnology Innovation Organization (BIO) leaders and member companies. CLS is
California Life Sciences recognizes BIO leaders and member companies Read More »
The WTO IP waiver for COVID-19 vaccines was never about vaccine distribution—it was a political calculation, according to Hans Sauer, Deputy General Counsel for
WTO IP waiver was always political: BIO’s patent lawyer breaks it down Read More »
The Inflation Reduction Act (IRA), signed into law on August 16, offered historic investments in energy security and climate change. However, the legislation also
AZBio President: IRA could have ‘long-term, unintended consequences’ Read More »
Rachel King was enjoying her retirement. When the COVID-19 pandemic hit, King found herself with a chance to refocus and ask herself what was
Meet Rachel King, BIO’s new interim CEO and a champion of the biotech industry Read More »
What did we learn on Day 1 of the Biotechnology Innovation Organization (BIO) Patient and Health Advocacy Summit in Washington, D.C.? It’s all about
What we learned on Day 1 of the Patient and Health Advocacy Summit Read More »
Every member of the Council of State Bioscience Associations (CSBA) signed a letter to President Biden expressing serious concerns with the proposed expansion of a
Expanding WTO IP waiver would hurt SMEs, CSBA tells Biden Read More »
The Biotechnology Innovation Organization (BIO) kicked off Day One of its two-day Patient and Health Advocacy Summit with a welcome from Eric Dube, President
